89bio's Pegozafermin Is Now Gaining Momentum

Group 1 - 89bio is focusing on Pegozafermin, which utilizes a fibroblast growth factor 21 (FGF21) approach to address metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG) [1] - Pegozafermin is currently in advanced trials for both MASH and SHTG, with topline data for SHTG expected to be released by the second half of the year [1]